Cofactor Genomics Announces Clinical Validation of its Tumor Immune-Profiling Assay, ImmunoPrismTM
October 02, 2018 08:00 ET | Cofactor Genomics
CAP/CLIA validation of ImmunoPrismTM furthers Cofactor’s mission of leveraging RNA to build unique, transformative assays informing critical clinical decisions SAN FRANCISCO, Oct. 02, 2018 (GLOBE...
Cofactor Genomics Launches Paragon, a Comprehensive Quantitative Solid Tumor Immune Profiling Assay
February 08, 2018 08:00 ET | Cofactor Genomics
SAN FRANCISCO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the commercial launch of Paragon, a solid tumor...